<DOC>
	<DOCNO>NCT02291913</DOCNO>
	<brief_summary>Many patient ER-positive PR-positive breast cancer treat endocrine therapy . Although ER/PR-positive tumor initially respond hormonal therapy , patient often experience disease progression . Everolimus , combination exemestane , show activity endocrine-resistant disease . This study evaluate efficacy Everolimus+ anti-estrogen therapy patient ER-positive metastatic breast cancer progress receive anti-estrogen therapy .</brief_summary>
	<brief_title>Everolimus Combined With Anti-estrogen Therapy Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer</brief_title>
	<detailed_description>This multi-centered , open-labeled , Phase II study metastastic breast cancer ( MBC ) . The patient population include locally recurrent MBC patient cytologically histologically confirm hormone receptor-positive breast cancer demonstrate disease progression prior anti-estrogen therapy therapy . Investigators propose evaluate efficacy Everolimus patient ER-positive ( estrogen receptor-positive ) metastatic breast cancer progress anti-estrogen therapy . Forty-six ( 46 ) patient plan enrollment trial .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Estrogen Receptor Modulators</mesh_term>
	<mesh_term>Estrogen Antagonists</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>1 . Histologic diagnosis unresectable , locally recurrent MBC . 2 . ER and/or PRpositive tumor stain immunohistochemistry ( IHC ) base recent biopsy . 3 . Only 1 previous chemotherapy regimen MBC . Patients progress receive adjuvant endocrine therapy progress &lt; 12 month completion adjuvant endocrine therapy eligible . 4 . Progressed antiestrogen therapy ( tamoxifen , fulvestrant , anastrozole , letrozole , exemestane , toremifine , LHRH agonists conjunction antiestrogen therapy ) define : Recurrence , within 12 month end antiestrogen therapy early stage breast cancer , Progression , within one month antiestrogen therapy locally advance metastatic breast cancer . Note : No washout antiestrogen therapy require . Antiestrogen therapy last treatment prior study entry . 5 . Postmenopausal pre/perimenopausal woman tamoxifen . LHRH agonist may use render ovarian suppression postmenopausal range estradiol FSH per institutional guideline . 6 . HER2negative breast cancer , define follow : Fluorescent In Situ Hybridization ( FISH ) negative ( FISH ratio &lt; 2.0 ) , IHC 01+ , IHC 23+ AND FISHnegative ( FISH ratio &lt; 2.0 ) . 7 . Measureable disease measure Response Evaluation Criteria Solid Tumors ( RECIST ) criteria version 1.1 evaluable bone lesion , lytic mixed , absence measureable disease RECIST criterion . 8 . Adequate hematologic , hepatic renal function . 9. International normalize ratio ( INR ) ≤1.5 prothrombin time ( PT ) /partial thromboplastin time ( PTT ) within normal limit ( WNL ) institution ( patient anticoagulation therapy ) . 10 . Age ≥ 18 year . 11 . ECOG Performance Status score 02 . 12 . Life expectancy ≥ 12 week . 1 . Previous therapy know intolerance/hypersensitivity approve investigational mTOR inhibitor ( e.g. , temsirolimus , everolimus , sirolimus ) . 2 . Patients ≤21 day recent chemotherapy recover side effect . 3 . Use investigational drug ≤21 day 5 halflives ( whichever short ) prior first dose everolimus . For investigational drug 5 halflives ≤21 day , minimum 10 day termination investigational drug administration everolimus require . 4 . Wide field radiotherapy ( include therapeutic radioisotope strontium 89 ) administer ≤28 day limit field radiation palliation ≤7 day metastatic disease prior first dose everolimus recover side effect therapy . 5 . Previously untreated brain metastasis . Patients receive radiation surgery brain metastasis eligible evidence central nervous system ( CNS ) disease progression , least 2 week elapse since treatment . Patients permit receive enzyme induce antiepileptic drug ( EIAEDs ) study receive chronic corticosteroid therapy CNS metastasis . 6 . Patients know active hepatitis B ( HBV ) hepatitis C ( HCV ) infection . Patients risk factor hepatitis must HBV DNA HCV RNA test PCR , ineligible test positive . 7 . Patients receive immunization attenuate live vaccine within 1 week study entry study period . NOTE : There additional inclusion/exclusion criterion . The study center determine patient eligibility respond question .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ER-Positive Breast Cancer</keyword>
	<keyword>HER2-Negative Breast Cancer</keyword>
	<keyword>everolimus</keyword>
	<keyword>anti-estrogen therapy</keyword>
	<keyword>PR-Positive Breast Cancer</keyword>
	<keyword>Afinitor</keyword>
</DOC>